Company / EPS (Diluted)
IGC Pharma, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.22
FY2025
5-year range
-$0.22 / -$0.19
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has declined for 3 consecutive years, from $-0.06 in FY2019 to $-0.22 in FY2025.
Based on SEC 10-K filings.
-0.22 in FY2025.
Declined from $-0.13 to $-0.22 over the past 5 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Peak eps (diluted) was recorded in FY2019.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.22 | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -$0.19 | -46.2% |
| FY2020 | -$0.13 | -116.7% |
| FY2019 | -$0.06 | +14.3% |
| FY2018 | -$0.07 | +58.8% |
| FY2017 | -$0.17 | +45.2% |
| FY2016 | -$0.31 | +16.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026